Home › Research & Development

Research & Development

Targeting eradication

MMV’s aim is to build a strong portfolio of molecules leading to a new generation of medicines that will be critical to the arsenal needed to eradicate malaria. Our R & D strategic objectives include:

Our project portfolio is managed through a rigorous process, and each project is evaluated by the Expert Scientific Advisory Committee (ESAC).

Essential information for scientists

Here you will find all the information and resources you need to work with MMV: information about our policies, key scientific documents and more. Popular documents:

R&D process

Discover, develop, deliver: it takes between 13-15 years to discover and develop a new antimalarial ready to be delivered to those in need. This slideshow walks you the steps involved in this complex process.

Optimizing artemisinin production

WHO and MMV have brought together stakeholders in the field of artemisinin production and extraction.

Science team

MMV's project portfolio is jointly managed by MMV's Science team. Chief Scientific Officer: Tim Wells.

Contact us

Curing malaria

Existing antimalarials have complex dosing regimes and target mainly falciparum malaria. MMV is seeking both a one-dose cure for falciparum malaria and a radical cure of vivax (relapsing) malaria.

Tackling resistance

Emerging drug resistance to artemisinin is a warning sign that we urgently need new classes of antimalarials. MMV is working to find ways to overcome resistance to current and future medicines.

Blocking transmission

New medicines that block the transmission of the parasite from patient to patient are vital if we are to defeat malaria. MMV is working to accelerate the development of these medicines.